|Day Low/High||85.46 / 86.86|
|52 Wk Low/High||62.55 / 101.28|
The interest areas of these investors span health care, hotels and international intrigue. Real Money takes a quick look at what they may discuss Wednesday.
The M&A activity is an incredible and a welcome sign.
This earnings season continues to disappoint, and technology names are leading the downward charge.
It's important to focus on hitting singles in this overbought and earnings-starved environment.
Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.
This will still be fourth quarter in a row that profits have declined year over year.
U.S. indices look to reverse yesterday's losses as crude prices continue their climb.
With low multiples and solid yields, these names look good for the long term.
ABBV is rising, and the current action could be the start of a strong move higher.
In this choppy market, the sweet spot is large-caps with these three core attributes.
I am starting to get more confident that the small caps are ready to bounce.
I like cheap smaller caps with little to no exposure to the global economy.
A breakdown below $52 should be the tipping point for further declines in ABBV.
If I had to guess, today's sharp rally was a function of monthly inflows, technical breakouts and programs. But it is only a guess. However, you will watch in the business media all the talking heads who liked yesterday's market and purchased opport...
Valuations of some small-cap concerns, such as Relypsa, are ridiculously cheap.
I started the day giving my bona fide and unadulterated and honest view of Berkshire Hathaway (BRK.B) in a two-part opening missive, which is here and here. Today, for a change, an inside day bereft of much volatility. Oops, wait. Not so much now i...
Some names should do well regardless of who becomes the next president.
Some stocks should do well regardless of who is the next president.
I am not ready to go full "risk on," but it's nice to see the market out of its cage.
The electrics have been crackling, but the group has more downside risk than currently perceived.
They offer impressive free cash flow, great balance sheets, evolving pipelines and nice dividend yields.
The market's major indices are getting worse as the morning progresses. There are deep losses across the board, with the Nasdaq Composite down nearly 3% at last check. Maybe we'll get some relief from the European markets closing. Oil is holding its...
In a year's time, investors may look back and think this was a great entry point.
Celgene, AbbVie and Gilead are set to report earnings. Here's what to look for.